Replies to post #134620 on Biotech Values

[DewDiligence]

Re: Largest-ever biotech buyout premium in medium/large deal

We probably should consider the premium paid for AnorMed Inc. because that stock went from the $4's to the final $13.50 with multiple bids unsolicited bids from both Millennium and Genzyme in 2006.

Even so, the nominal deal value was barely more than $500M—and it was less than $500M on an enterprise value basis, i.e. when excluding the acquired company’s cash on hand.

So, although Millennium-AnorMed was a notable case and a good catch by you, it is not a counter-example to the claim in #msg-70636729 that the BMY-INHX deal has the largest premium ever paid in a biotech acquisition of more than $500M. If anyone knows of such a counter-example, please post.